TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24719126

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab (0.25 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy (AT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of intracoronary abciximab and aspiration thrombectomy
Number of subjects: 40
Study: 22387713

Group type: EXPERIMENTAL
Intervention: FASTED (24h fasting)
Number of subjects: 15

Group type: COMPARATOR
Intervention: FED (baseline)
Number of subjects: 15
Study: 19620075

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with butorphanol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia (PCEA) with morphine
Number of subjects: 60
Study: 16710430

Group type: EXPERIMENTAL
Intervention: Scleral buckling (group 1)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pars plana vitrectomy (PPV) (group 2)
Number of subjects: 43
Study: 15364776

Group type: EXPERIMENTAL
Intervention: Eptifibatide (IV bolus of 180 microg/kg body weight followed by continuous infusion of 2 microg/kg/min)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 356
Study: 11216965

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg twice daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 10513460

Group type: EXPERIMENTAL
Intervention: Adderall 10 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Adderall 15 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Adderall 20 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 8078528

Group type: EXPERIMENTAL
Intervention: Combination of adjustment in medications, behavioral instructions, and exercise programs (intervention group, 153 subjects)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual health care plus social visits (control group, 148 subjects)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Combination of adjustment in medications, behavioral instructions, and exercise programs (intervention group)
Number of subjects: 301
Study: 2676390

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1249566

Group type: EXPERIMENTAL
Intervention: Stimulant drug treatment (continued medication)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (matched)
Number of subjects: 72
Study: 31233169

Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment
Number of subjects: 70
Study: 29441886

Group type: EXPERIMENTAL
Intervention: Mucosolvan® inhalation in addition to conventional treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment only (Control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mucosolvan® inhalation
Number of subjects: 80
Study: 25942443

Group type: EXPERIMENTAL
Intervention: Oral Valganciclovir (VGCV) 900mg/day
Number of subjects: 161

Group type: COMPARATOR
Intervention: Intravenous Ganciclovir (GCV) 5mg/kg twice daily
Number of subjects: 161
Study: 22648280

Group type: EXPERIMENTAL
Intervention: Simulated soldier patrol (SP) at 42°C, 9% relative humidity for 2.5 hours with 400 mg ibuprofen
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Simulated soldier patrol (SP) at room temperature for 2.5 hours with 400 mg ibuprofen
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham soldier patrol (SP)
Number of subjects: 13
Study: 21368025

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) at low intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) at high intensity
Number of subjects: 0
Study: 19090503

Group type: EXPERIMENTAL
Intervention: Ramelteon 16 mg nightly for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo nightly for 6 months
Number of subjects: 0
Study: 16373650

Group type: EXPERIMENTAL
Intervention: Color duplex sonography (CDS)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Cervical MRI and MRA
Number of subjects: 177
Study: 15296703

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 19768
Study: 11253266

Group type: EXPERIMENTAL
Intervention: 75 mg of acetylsalicylic acid (ASA) daily
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Lowering diastolic BP to about 80 mm Hg
Number of subjects: 18790

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18790
Study: 9349075

Group type: EXPERIMENTAL
Intervention: Cricoid pressure applied
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cricoid pressure in an upward and backward direction
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Standard technique of cricoid pressure with neck support
Number of subjects: 50
Study: 1588361

Group type: EXPERIMENTAL
Intervention: Simulated treatment group (cholesterol reduction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated placebo group (no cholesterol reduction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observed incidence in LRC‐CPPT
Number of subjects: 0
Study: 4002096

Group type: EXPERIMENTAL
Intervention: Single dose of 1 g of amoxicillin plus 1 g of probenecid (group 1)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 1 g of amoxicillin twice a day for two days (group 2)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 0.75 mg of amoxicillin three times a day for seven days (group 3)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Groups 1 and 2 combined
Number of subjects: 92
Study: 31863755

Group type: EXPERIMENTAL
Intervention: Preventive protocol consisting of intermittent ventilation of the right lung, restoration of bilateral ventilation, administration of mannitol before unclamping the aorta, and institution of mild hypothermia.
Number of subjects: 469

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 469
Study: 28511588

Group type: EXPERIMENTAL
Intervention: Satiety-stimulating product
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxing product
Number of subjects: 0
Study: 26712041

Group type: EXPERIMENTAL
Intervention: 0.5% AP736 formulation (test formulation; n = 24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vehicle formulation (vehicle control; n = 24)
Number of subjects: 48
Study: 25399731

Group type: EXPERIMENTAL
Intervention: Lisinopril and ARB (telmisartan)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 486
Study: 23169180

Group type: EXPERIMENTAL
Intervention: Fondaparinux combined with intermittent pneumatic compression (IPC)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Intermittent pneumatic compression (IPC) alone
Number of subjects: 137
Study: 19806411

Group type: EXPERIMENTAL
Intervention: Porous tantalum implant
Number of subjects: 101

Group type: COMPARATOR
Intervention: Autologous local tibial bone graft
Number of subjects: 101
Study: 18606612

Group type: EXPERIMENTAL
Intervention: cTnI levels >0.01 microg/L
Number of subjects: 1005
Study: 15748464

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 U subcutaneously once weekly
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 94
Study: 11870808

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10730720

Group type: EXPERIMENTAL
Intervention: Implant treatment (preference)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Conventional treatment (preference)
Number of subjects: 136
Study: 9187986

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (Group R, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5% glucose (Group G, n = 20)
Number of subjects: 40
Study: 1440488

Group type: EXPERIMENTAL
Intervention: Real-time B-mode ultrasonography for proximal DVT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Real-time B-mode ultrasonography for overall DVT
Number of subjects: 100
Study: 2986424

Group type: EXPERIMENTAL
Intervention: hpGRF 3.3 to 50 micrograms i.v. bolus
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: hpGRF 100 micrograms/h infusion for 2 to 5 hours after a bolus of 50 micrograms hpGRF
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: hpGRF 100 micrograms to 14 patients with active acromegaly
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30768188

Group type: EXPERIMENTAL
Intervention: Sepsis present during hospitalization
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Sepsis-associated deaths
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Suboptimal care (delays in antibiotics)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Preventability of sepsis-associated deaths
Number of subjects: 568
Study: 29367653

Group type: EXPERIMENTAL
Intervention: Radiomic signature derived from pre-therapy imaging using Intensity Direct and Neighbor Intensity Difference methods.
Number of subjects: 465
Study: 26434738

Group type: EXPERIMENTAL
Intervention: Calcipotriol applied to the entirety of the previous lesion (group A)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Calcipotriol applied only to the remaining lesion (group B)
Number of subjects: 29
Study: 25336707

Group type: EXPERIMENTAL
Intervention: Atosiban (6.75 mg bolus, followed by 18 mg/h for 1 hour, then 6 mg/h for 2 hours)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo (i.v. normal saline)
Number of subjects: 800
Study: 22037572

Group type: EXPERIMENTAL
Intervention: Active PRFE device
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 18
Study: 20551724

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/d
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 18292297

Group type: EXPERIMENTAL
Intervention: Mild overnight hypoxia (arterial oxygen saturation approximately 85%)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Medical air (normoxia)
Number of subjects: 14
Study: 15842040

Group type: EXPERIMENTAL
Intervention: Point-of-care monitor (ProTime, International Technidyne Corporation)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Laboratory INR measurements
Number of subjects: 55
Study: 12520569

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 30 mg/kg 30 min before liver resection
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no steroid administration)
Number of subjects: 53
Study: 10383513

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 317

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 317
Study: 8884672

Group type: EXPERIMENTAL
Intervention: Usual care supplemented with feedback of patient-reported mental health information
Number of subjects: 573

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 573
Study: 31629334

Group type: EXPERIMENTAL
Intervention: Low-intensity aerobic exercise (LIAEX)
Number of subjects: 3
Study: 29855069

Group type: EXPERIMENTAL
Intervention: Device-supported sensorimotor training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard splint therapy
Number of subjects: 45
Study: 27099480

Group type: EXPERIMENTAL
Intervention: Multicomponent dyadic intervention (home‐based physical exercise training, psycho‐education, communication skills training, and pleasant activities training for 3 months)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 111
Study: 24655485

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 27

Group type: COMPARATOR
Intervention: CHO + BCAA
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PLC
Number of subjects: 27
Study: 21540353

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Comparison group (Control)
Number of subjects: 67
Study: 21074013

Group type: EXPERIMENTAL
Intervention: 400 mcg buccal misoprostol
Number of subjects: 550

Group type: COMPARATOR
Intervention: 400 mcg sublingual misoprostol
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Both groups (buccal and sublingual)
Number of subjects: 550
Study: 17621572

Group type: EXPERIMENTAL
Intervention: Acapella device used for airway clearance sessions at home twice daily during oral antibiotic therapy (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual airway clearance sessions at home during oral antibiotic therapy (n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acapella device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual airway clearance
Number of subjects: 20
Study: 15618036

Group type: COMPARATOR
Intervention: Left Ventricular (LV) pacing
Number of subjects: 56

Group type: COMPARATOR
Intervention: Biventricular (BiV) pacing
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Right Ventricular (RV) pacing
Number of subjects: 56
Study: 12013377

Group type: EXPERIMENTAL
Intervention: Dynamic face stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correctly ordered and timed frame stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static face stimuli (control)
Number of subjects: 0
Study: 9933064

Group type: EXPERIMENTAL
Intervention: Group I (Alarm set to void at critical time)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Group II (Alarm to awaken for voiding after 2-3 hours)
Number of subjects: 125
Study: 8536677

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) at 900 mg/day or 1200 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2194029

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 360

Group type: COMPARATOR
Intervention: Atenolol, Captopril, Enalapril
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 360
Study: 343999

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31724507

Group type: EXPERIMENTAL
Intervention: Telephonic health coaching for at least 2 years
Number of subjects: 350

Group type: COMPARATOR
Intervention: Yearly biometric screening (Control)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Telephonic health coaching
Number of subjects: 350
Study: 29127431

Group type: EXPERIMENTAL
Intervention: Donor cornea with preservation time (PT) of 7 days or less (0-7d PT)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Donor cornea with preservation time (PT) of 8 to 14 days (8-14d PT)
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Longer PT (analyzed as days)
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: PT of 4 days or less
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: PT of 5 to 7 days
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: PT of 8 to 11 days
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: PT of 12 to 14 days
Number of subjects: 1090
Study: 25766863

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23325919

Group type: EXPERIMENTAL
Intervention: l‐[1‐(13)C]threonine enterally or parenterally
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: l‐[1‐(13)C]lysine enterally or parenterally
Number of subjects: 6
Study: 21295881

Group type: EXPERIMENTAL
Intervention: Reirradiation with various doses: 8 Gy single-dose, 5×3 Gy, 2×8 Gy, 5×4 Gy, single doses of 7 and 4 Gy.
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Reirradiation (various doses)
Number of subjects: 579
Study: 18930646

Group type: EXPERIMENTAL
Intervention: Salbutamol (400 mcg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 16
Study: 16750294

Group type: EXPERIMENTAL
Intervention: Dysport (Botulinum type A toxin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study: 14751650

Group type: EXPERIMENTAL
Intervention: Omapatrilat 10 mg
Number of subjects: 25302

Group type: COMPARATOR
Intervention: Enalapril 5 mg
Number of subjects: 25302
Study: 11148859

Group type: EXPERIMENTAL
Intervention: Test formulation (Zoltrix)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 24
Study: 9068312

Group type: EXPERIMENTAL
Intervention: One hour amphotericin B infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four hour amphotericin B infusion
Number of subjects: 0
Study: 8453190

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Broadband ultrasound attenuation (BUA)
Number of subjects: 1000
Study: 3010692

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atropine (0.04 mg/kg) with Propranolol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atropine (0.04 mg/kg) with Atenolol
Number of subjects: 9
Study: 28960513

Group type: EXPERIMENTAL
Intervention: Cooling both back and head (neck)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Back cooling alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Head (neck) cooling alone
Number of subjects: 16

Group type: COMPARATOR
Intervention: No cooling (control)
Number of subjects: 16
Study: 27217459

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative chemotherapy with 1,200 cGy TBI
Number of subjects: 101

Group type: COMPARATOR
Intervention: Nonmyeloablative chemotherapy without TBI
Number of subjects: 101
Study: 24939366

Group type: EXPERIMENTAL
Intervention: Partial uncinectomy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Total uncinectomy
Number of subjects: 25
Study: 23526959

Group type: EXPERIMENTAL
Intervention: Albendazole treatment every three months for 21 months
Number of subjects: 4004

Group type: COMPARATOR
Intervention: Placebo treatment every three months for 21 months
Number of subjects: 4004

Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 4004
Study: 21169142

Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.2 μg/kg per minute)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dopexamine (2 μg/kg per minute)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 42
Study: 17499419

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 100
Study: 15676129

Group type: EXPERIMENTAL
Intervention: Home hospitalization (HH) program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional hospitalization
Number of subjects: 40
Study: 12363466

Group type: EXPERIMENTAL
Intervention: Combined passive active immunisation with human specific Hepatitis B immunoglobulin (HEPABIG‐VHB Pharmaceuticals) and Hepatitis B vaccine (arm I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active immunisation along with interferon (arm II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined passive active immunisation with human specific Hepatitis B immunoglobulin (HEPABIG‐VHB Pharmaceuticals)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined passive active prophylaxis
Number of subjects: 60
Study: 10364782

Group type: EXPERIMENTAL
Intervention: 22.5% branched chain amino acids + 20% LCT
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 45% branched chain amino acids + 20% LCT
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 45% branched chain amino acids + 20% MCT/LCT
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (standard solution)
Number of subjects: 62
Study: 8529068

Group type: COMPARATOR
Intervention: Dopamine 1 microgram/kg/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dopamine 1 microgram/kg/min + Domperidone 30 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dopamine 3 micrograms/kg/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dopamine 1 and 3 micrograms/kg/min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study: 2406848

Group type: EXPERIMENTAL
Intervention: Gamma-hydroxybutyrate (GHB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7022973

Group type: EXPERIMENTAL
Intervention: E7H7 (ethambutol 15 mg/kg plus isoniazid 400 mg daily)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: E2H2 (ethambutol 45 mg/kg plus isoniazid 15 mg/kg twice a week)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: E1H2 (ethambutol 90 mg/kg plus isoniazid 15 mg/kg once a week plus isoniazid 15 mg/kg mid-way between the weekly doses)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: E1H1 (ethambutol 90 mg/kg plus isoniazid 15 mg/kg once a week)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: E7H7
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: E2H2
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: E1H2
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: E1H1
Number of subjects: 424
Study: 31092115

Group type: EXPERIMENTAL
Intervention: C8 Health Project participation
Number of subjects: 1500
Study: 30559477

Group type: EXPERIMENTAL
Intervention: Inference process model for subjective valuation
Number of subjects: 0
Study: 29231503

Group type: EXPERIMENTAL
Intervention: Combined therapy (acupuncture and western medication)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Western medication (ribavirin granules 10 mg/kg a day, three times a day for 3 days)
Number of subjects: 120
Study: 26387933

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0
Study: 22796064

Group type: EXPERIMENTAL
Intervention: Soybean/MCT/olive/fish emulsion (SMOFlipid, n = 34)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Soybean emulsion (Intralipid, control n = 39)
Number of subjects: 73
Study: 21476029

Group type: EXPERIMENTAL
Intervention: Ileal pouch-rectal muscle sheath anastomosis
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ileal pouch-anal anastomosis
Number of subjects: 22